An Open Label, Multicentre, Two Stage, Phase II Study To Evaluate Efficacy And Safety Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression.
Phase of Trial: Phase II
Latest Information Update: 08 Jun 2016
At a glance
- Drugs P 276 (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms ENVER
- Sponsors Piramal Enterprises
- 08 Jun 2016 Last checked against Australian New Zealand Clinical Trials Registry record.
- 01 Nov 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Jan 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.